ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir disoproxil as fumarate - טבליות מצופות פילם - emtricitabine 200 mg; tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age.

ישראל - עברית - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir disoproxil as fumarate - טבליות מצופות פילם - emtricitabine 200 mg; tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - truvada is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age.

ישראל - עברית - Ministry of Health

teva israel ltd - tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg - tenofovir disoproxil - tenofovir disoproxil - indicated for the treatment of : 1. hiv 1 infected adults and pediatric patients 12 years of age and older in combination with other antiretroviral medicinal products for the treatment of hiv.2. chronic hepatitis b in adults with: • compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. • decompensated liver disease.

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 150 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - maraviroc - טבליות מצופות פילם - maraviroc 300 mg - maraviroc - maraviroc - celsentri is a ccr5 co-receptor antagonist indicated for combination antiretroviral treatment of adults infected with only ccr5-tropic hiv-1.• in treatment-na?ve subjects, more subjects treated with celsentri experienced virologic failure and developed lamivudine resistance compared to efavirenz.• tropism testing with a highly sensitive tropism assay is required for the appropriate use of celsentri.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - קפסולות - mycophenolate mofetil 250 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - טבליות מצופות פילם - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.

ישראל - עברית - Ministry of Health

teva israel ltd - mycophenolate mofetil - טבליה - mycophenolate mofetil 500 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, in patients receiving allogenic cardiac transplants and in allogenic hepatic transplants. mycophenolate teva should be used concomitantly with ciclosporin and corticosteroids.